AWARD NUMBER: W81XWH-15-2-0031

TITLE: Novel Strategies to Improve Immunomodulation and Noninvasive Clinical Monitoring in VCA

PRINCIPAL INVESTIGATOR: Bohdan Pomahac, MD

CONTRACTING ORGANIZATION: Brigham and Women's Hospital Boston, MA 02115-6110

REPORT DATE: August 14, 2019

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command

Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;

Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

Interpretation Interpr					Form Approved				
Pade: approximate barder forms. Cellender of the matter is concept. In additional terms of the first or the output barder is concept. The second of the first or the output barder is concept. The second of the sec	REPORT DO	JCUMENTATIO	N PAGE		OMB No. 0704-0188				
1. REPORT TOPE 3. DATES COVERED 1.5.UU2015 1.4.UU2019 A. THLE AND SUBTITLE 3. DATES COVERED Novel. Strategies to Improve Immunomodulation and Noninvasive 5. CARK ANT NUMBER Clinical Monitoring in VCA 5. CROGRAM ELEMENT NUMBER 6. AUTHOR(S) 5. PROGRAM ELEMENT NUMBER 6. AUTHOR(S) 5. PROGRAM ELEMENT NUMBER 7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) 5. PROFORMING ORGANIZATION RAME(S) AND ADDRESS(ES) Brigham and Women's Hospital 7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) 8. PERFORMING ORGANIZATION REPORT Dirigham and Women's Hospital 7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) 10. SPONSOR/MONITOR'S ACCONVM(S) U.S. Army Medical Research and Materiel Command 6. PERFORMING ORGANIZATION REPORT 11. SPONSOR/MONITOR'S ACCONVM(S) 12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY NOTES 13. SUPPLEMENTARY NOTES 14. ABSTRACT Surger Concols with Minimal Side effects. Our specific alms are: (1) Establishing the efficacy of a low-dose IL-2 protocol at enabling functional restoration of vounded warriors. Our overarching goal is enabling functional and aesthetic restoration monotherapy in recipients of VCA. (2) Exploring correlations between cellular and molecular immunosuppression to strolimus monotherapy in recipients of VCA. (2) Exploring correlations	Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.								
AUGUST 2019 Annual 15.UUC2018 - 14.UU2019 4. TTLE AND SUBTILE 56. CONTRACT NUMBER 56. CONTRACT NUMBER Novel Strategies to Improve Immunomodulation and Noninvasive 56. GRANT NUMBER Clinical Monitoring in VCA 56. GRANT NUMBER 6. AUTHOR(S) 56. FRANT NUMBER 7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) 8. PERFORMING ORGANIZATION REPORT Brigham and Women's Hospital 75. Francis St Booston MA 02115 8. PERFORMING ORGANIZATION REPORT NUMBER 10. SPONSOR/MONITOR'S ACRONYM(S) U.S. Army Medical Research and Materiel Command 11. SPONSOR/MONITOR'S ACRONYM(S) For Detrick, Maryland 21702-5012 10. SPONSOR/MONITOR'S REPORT VUMBER(S) 11. SPONSOR/MONITOR'S REPORT NUMBER(S) 11. SPONSOR/MONITOR'S REPORT Startigutton / AVAILABILITY STATEMENT 11. SPONSOR/MONITOR'S REPORT Startigut	1. REPORT DATE	2. REPORT TYPE		3. E	DATES COVERED				
4. TTLE AND SUBTITLE 5s. CONTRACT NUMBER Novel. Strategies to Improve Immunomodulation and Noninvasive 5s. CARNAT NUMBER Clinical Monitoring in VCA 5s. CARNAT NUMBER 6. AUTHOR(S) 5s. PROGRAM FLEMENT NUMBER 7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) 5s. FASK NUMBER Brigham and Women's Hospital 7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) 8. PERFORMING ORGANIZATION REPORT Brigham and Women's Hospital 7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) 10. SPONSOR/MONITOR'S ACCONYM(S) U.S. Army Medical Research and Materiel Command 7. PERFORMING ORGANIZATION REPORT 11. SPONSOR/MONITOR'S ACCONYM(S) U.S. Army Medical Research and Materiel Command 11. SPONSOR/MONITOR'S REPORT 11. SPONSOR/MONITOR'S REPORT VUS. Sharny Medical Research and Materiel Command 11. SPONSOR/MONITOR'S REPORT 11. SPONSOR/MONITOR'S REPORT 12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY NOTES 13. SUPPLEMENTARY NOTES 14. ABSTRACT Sater CA Our overarching goal is enabling functional restoration of wounded warriors. Our overarching goal is enabling functional and aesthetic restoration of wounded warriors. Our overarching goal is enabling functional and aesthetic restoration of out of a sub-ocol s with imminal side effects. Our specific aims are: (1) Establishing the efficacy of a lo	AUGUST 2019	Annual		1	5JUL2018 - 14JUL2019				
Novel Strategies to Improve Immunomodulation and Noninvasive Clinical Monitoring in VCA Sb. GRANT NUMBER MR140159 6. AUTHOR(S) Sc. PROGRAM ELEMENT NUMBER Sc. TASK NUMBER 6. AUTHOR(S) Sc. TASK NUMBER 7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Sc. TASK NUMBER Brigham and Women's Hospital 75 Francis St Boston MA 02115 Sc. PROGRAM ELEMENT NUMBER 9. SPONSORING / MONTORING AGENCY NAME(S) AND ADDRESS(ES) II. SPONSOR/MONITOR'S ACRONYM(S) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 10. SPONSOR/MONITOR'S ACRONYM(S) 12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY NOTES 14. ABSTRACT Safely minimizing the risks associated with vascularized composite allotransplantation (VCA) is crucial for functional restoration of vounded warriors. Our overarching goal is enabling functional and aesthetic restoration to patients with severe, unreconstructable vascularized composite tissue defects by Safe VCA protocols with minimal side effects. Our specific aims are: (1) Establishing the efficacy of a low-dose IL-2 protocol at enabling minimization of immunosuppression to sirolimus monotherapy In recipients of VCA. (2) Exploring correlations between cellular and molecular immunoasays performed in specimens from VCA recipients (and their donors) with clinical observations of stablity and rejection. In future trials, these assays can be developed into tools that prospectively predict rejection and tolerance in VCA, and (3) Implementing next-generation methods to supplement and potentially overcome limita	4. TITLE AND SUBTITLE			5a. W8	CONTRACT NUMBER 1XWH-15-2-0031				
Clinical Monitoring in VCA G. AUTHOR(S) G.	Novel Strategies to Impro	ve Immunomodulati	on and Noninvas	sive 5h					
6. AUTHOR(S) Sc. PROGRAM ELEMENT NUMBER 6. AUTHOR(S) Sc. PROGRAM ELEMENT NUMBER 6. AUTHOR(S) Sc. PROGRAM ELEMENT NUMBER 7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) S. PERFORMING ORGANIZATION REPORT Brigham and Women's Hospital 75 Francis St. Poston MA 02115 S. PORSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSOR/MONITOR'S ACRONYM(S) U.S. Army Medical Research and Materiel Command This SPONSOR/MONITOR'S REPORT Fort Detrick, Maryland 21702-5012 11. SPONSOR/MONITOR'S REPORT 12. DISTRIBUTION / AVAILABILITY STATEMENT NUMBER(S) Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY NOTES 14. ABSTRACT SafeTy minimizing the risks associated with vascularized composite allotransplantation (VCA) is crucial for functional restoration of patients with severe, unreconstructable vascularized composite tissue defects by safe VCA protocols with minimal side effects. Our specific aims are: (1) Establishing the efficacy of a low-dose IL-2 protocol at enabling minimization of immunosuppression to strolimus monotherapy in recipients of VCA. (2) Exploring correlations between cellular and molecular immunoasays performed in specimens from VCA recipients (and their donors) with clinical observations of stability and rejection. In future trials, these assays can be developed into tools that prospectively predict rejection and tolerance in VCA, and (3) Implementing next-	Clinical Monitoring in VC	A		MR	IR140159				
6. AUTHOR(S) 5. HOUBECT NUMBER 5. TASK NUMBER 5. TASK NUMBER 5. TASK NUMBER 5. TASK NUMBER 5. TORCHING ORGANIZATION NAME(S) AND ADDRESS(ES) Brigham and Women's Hospital 75 Francis St Boston MA 02115 5. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 10. SPONSORIMONITOR'S ACRONYM(S) 11. SPONSORIMONITOR'S ACRONYM(S) 12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY NOTES 14. ABSTRACT Safety minimizing the risks associated with vascularized composite allotransplantation (vcA) functional and aesthetic restoration of wounded varriors. Our overarching goal is enabling functional and aesthetic restoration to patients with severe, unreconstructable vascularized composite tissue defects by safe VCA protocols with minimal side effects. Our specific aims are: (1) Establishing the efficacy of a low-dose IL-2 protocol at enabling minimization of immunosuppression to sirolimus monotherapy in recipients of VCA. (2) Exploring correlations between cellular and molecular immunoasays performed in specimens (1 on VCA recipients (and their donors) with clinical observations of stability and rejection. In future trials, these assays can be developed into tools that prospectively predict rejection and bloincircoscopy (UBN). We are enrolling 5 subjects for VCA. <3 months after VCA, once recipient and allograft are stable, we will administer an IL-2 based protocol intended to enable minimization of immunosuppression to sirolimus monotherapy. Afterwards, immunosuppression will be weaned. SUBJECT TERMS: NONE LISTED 16. SECURITY CLASSIFICATION OF: a. REPORT Unclassified Unclassified Unclassified Unclassified Unclassified Unclassified Unclassified Unclassified Unclassified Unclassified Unclassified Unclassified Unclassified Unclassified Unclassified Unclassified Unclassified Unclassified Uncla				5c.	c. PROGRAM ELEMENT NUMBER				
Set Task Number 5. TASK Number 5. WORK UNIT NUMBER 5. PERFORMING ORGANIZATION NAME(\$) AND ADDRESS(E\$) Brigham and Women's Hospital 75 Francis St. Boston MA 02115 9. SPONSORING / MONITORING AGENCY NAME(\$) AND ADDRESS(E\$) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY NOTES 44. ABSTRACT Safe CAC protocols with minimal side effects. Our specific aims composite allotransplantation (VCA) is crucial for functional restoration of wounded warriors. Our overarching goal is enabling functional and aesthetic restoration to patients with severe, unreconstructable vascularized composite allotransplantation of (VCA) is crucial for functional restoration of stability and rejection. In future trials, these assays can be developed into tools that prospectively predict rejection and tolerance in VCA, eads (3) Implementing next-generation methods to supplement and potentially overcome limitations of estabilished methods such as histology and ultrasound biomicroscopy (UBN). We are enrolling 5 subjects for VCA. <3 months after VCA, once recipient and allograft are stable, we will administer an IL-2 based protocol intended to enable minimization of immunosuppression to strolimus monotherapy. Afterwards, immunosupression vill be weaned.	6. AUTHOR(S)				PROJECT NUMBER				
5f. WORK UNIT NUMBER 7. FERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Brigham and Women's Hospital 75 Francis St Boston MA 02115 9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY NOTES 14. ABSTRACT Safe of this of the efficacy of a low-dose IL-2 protocol at enabling minimization of immunosuppression to sirolinus monotherapy in recipients of vertice and molecular immunoassays performed in specimens from VCA recipients (ad assays can be developed into tools that prospectively predict rejection. In future trials, these assays can be developed into tools that prospectively predict rejection. In future trials, these assays can be developed into tools that prospectively predict rejection. In future trials, these assays can be developed into tools that prospectively predict rejection and tolerance in VCA, once recipient and allograft are stable, we will administer an IL-2 based protocol intended to enable minimization of immunosuppression to sirolinus monotherapy. Afterwards, immunosuppression will be weaned. SUBJECT TERMS: NONE LISTED 16. SECURITY CLASSIFICATION OF: a. REPORT b. ABSTRACT b. RESTRACT study 17. LINITATION				TASK NUMBER					
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) 8. PERFORMING ORGANIZATION REPORT NUMBER Brigham and Women's Hospital 75 Francis St Boston MA 02115 9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSOR/MONITOR'S ACRONYM(S) U.S. Army Medical Research and Materiel Command 11. SPONSOR/MONITOR'S ACRONYM(S) Fort Detrick, Maryland 21702-5012 11. SPONSOR/MONITOR'S ACRONYM(S) 12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY NOTES 14. ABSTRACT 14. ABSTRACT composite tissue defects by safe VCA protocols with minimal side effects. Our specific aims are: (1) Establishing the efficacy of a low-dose IL-2 protocol at enabling minimization of immunosuppression to sirolinus monotherapy in recipients of VCA. (2) Exploring correlations between cellular and molecular immunoassays performed in specimens from VCA recipients (and their donors) with clinical observations of stability and rejection. In future trials, these assays can be developed into tools that prospectively predict rejection and tolerance in VCA, and (3) Implementing next-generation methods to supplement and potentially overcome limitation of immunosuppression to sirolinus monotherapy. Afterwards, immunosuppression will be weaned. SUBJECT TERMS: NONE LISTED 11. LIMITATION of PAGES 16. SECURITY CLASSIFICATION OF: 11. LIMITATION OF PAGES a. REPORT b. ABSTRACT c. THIS PAGE Unclassified				5f.	. WORK UNIT NUMBER				
Brigham and Women's Hospital 75 Francis St Boston MA 02115 10. SPONSORIMG / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSOR/MONITOR'S ACRONYM(S) 9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 11. SPONSOR/MONITOR'S ACRONYM(S) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 11. SPONSOR/MONITOR'S REPORT NUMBER(S) 12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY NOTES 14. ABSTRACT Safely minimizing the risks associated with vascularized composite allotransplantation (vCA) is crucial for functional restoration to patients with severe, unreconstructable vascularized composite tissue defects by safe VCA protocols with minimal side effects. Our specific aims are: (1) Establishing the efficacy of a low-dose IL-2 protocol at enabling minimization of immunosuppression to sirolinus monotherapy in recipients of VCA. (2) Exploring correlations between cellular and molecular immunoasays performed in specimens from VCA recipients (and their donors) with clinical observations of stability and rejection. In future trials, these assays can be developed into tools that prospectively predict rejection and tolerance in VCA, and (3) Implementing next-generation methods to supplement and potentially overcome limitations of established methods such as histology and ultrasound biomicroscopy (UBM). We are enrolling 5 subjects for VCA. <3 months after VCA, once recipient and allograft are stable, we will administer an IL-2 based protocol intended to enable minimization of immunosuppression to sirolinus monotherapy. Afterwards, immunosuppression will be weaned. SUBJECT TE	7. PERFORMING ORGANIZATION NAME	E(S) AND ADDRESS(ES)		8. F N	8. PERFORMING ORGANIZATION REPORT NUMBER				
75 Francis St Boston MA 02115 10. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSOR/MONITOR'S ACRONYM(S) 9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSOR/MONITOR'S ACRONYM(S) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 11. SPONSOR/MONITOR'S REPORT NUMBER(S) 12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY NOTES 4. ABSTRACT Safely minimizing the risks associated with vascularized composite allotransplantation (VCA) is crucial for functional restoration of wounded warriors. Our overarching goal is enabling functional and aesthetic restoration to patients with severe, unreconstructable vascularized composite tissue defects by safe VCA protocols with minimal side effects. Our specific aims are: (1) Establishing the efficacy of a low-dose IL-2 protocol at enabling minimization of immunosuppression to sirolimus monotherapy in recipients of VCA. (2) Exploring correlations between cellular and molecular immunoasays performed in specimens from VCA recipients (and their donors) with clinical observations of stability and rejection. In future trials, these assays can be developed into tools that prospectively predict rejection and tolerance in VCA, and (3) Implementing next-generation methods to supplement and potentially overcome limitations of established methods such as histology and ultrasound biomicroscopy (UBM). We are enrolling 5 subjects for VCA. <3 months after VCA, once recipient and allograft are stable, we will administer an IL-2 based protocol intended to enable minimization of immunosuppression to sirolimus monotherapy. Afterwards, immunosuppression wil	Brigham and Women's Hospi	tal							
Boston WA 02115 9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSOR/MONITOR'S ACRONYM(S) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 11. SPONSOR/MONITOR'S REPORT NUMBER(S) 12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY NOTES 14. ABSTRACT Safely minimizing the risks associated with vascularized composite allotransplantation (VCA) is crucial for functional restoration of wounded warriors. Our overarching goal is enabling functional and aesthetic restoration to patients with severe, unreconstructable vascularized composite tissue defects by safe VCA protocols with minimal side effects. Our specific alms are: (1) Establishing the efficacy of a low-dose IL-2 protocol at enabling minimization of immunosuppression to sirolimus monotherapy in recipients of VCA. (2) Exploring correlations between cellular and molecular immunoasays performed in specimens from VCA recipients (and their donors) with clinical observations of stability and rejection. In future trials, these assays can be developed into tools that prospectively predict rejection and tolerance in VCA, and (3) Implementing next-generation methods to supplement and potentially overcome limitations of established methods such as histology and ultrasound biomicroscopy (UBM). We are enrolling 5 subjects for VCA. <3 months after VCA, once recipient and allograft are stable, we will administer an IL-2 based protocol intended to enable minimization of immunosuppression to sirolimus monotherapy. Afterwards, immunosuppression will be weaned. SUBJECT TERMS: NONE LISTED 16. SECURITY CLASSIFICATION OF: 17. LIMITA	75 Francis St								
9. SPONSORING / MONITORING AGENCY NAME(\$) AND ADDRESS(E\$) 10. SPONSOR/MONITOR'S ACRONYM(\$) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 11. SPONSOR/MONITOR'S ACRONYM(\$) 12. DISTRIBUTION / AVAILABILITY STATEMENT 11. SPONSOR/MONITOR'S REPORT NUMBER(\$) 13. SUPPLEMENTARY NOTES 13. SUPPLEMENTARY NOTES 14. ABSTRACT saffely minimizing the risks associated with vascularized composite allotransplantation (vCA) is crucial for functional restoration of wounded warriors. Our overarching goal is enabling functional and aesthetic restoration to patients with severe, unreconstructable vascularized composite tissue defects by safe VCA protocols with minimal side effects. Our specific ains are: (1) Establishing the efficacy of a low-dose IL-2 protocol at enabling minimization of immunosuppression to sirolimus monotherapy in recipients of VCA. (2) Exploring correlations between cellular and molecular immunoassays performed in specimens from VCA recipients (and their donors) with clinical observations of stability and rejection. In future trials, these assays can be developed into tools that prospectively predict rejection and tolerance in VCA, and (3) Implementing next-generation methods to supplement and potentially overcome limitations of established methods such as histology and ultrasound biomicroscopy (UBM). We are enrolling 5 subjects for VCA. <3 months after VCA, once recipient and allograft are stable, we will administer an IL-2 based protocol intended to enable minimization of immunosuppression to sirolimus monotherapy. Afterwards, immunosuppression will be weaned. SUBJECT TERMS: NONE LISTED 16. SECURITY CLASSIFICATION OF: 17. LIMITATION OF ABSTRACT Unclassified 18. NUMBER OF ABSTRACT Unclassified<	Boston MA 02115								
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSOR/MONITOR'S ACRONYM(S) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 11. SPONSOR/MONITOR'S REPORT NUMBER(S) 12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY NOTES 14. ABSTRACT SafeTy minimizing the risks associated with vascularized composite allotransplantation (VCA) is crucial for functional restoration of wounded warriors. Our overarching goal is enabling functional and aesthetic restoration to patients with severe, unreconstructable vascularized composite tissue defects by safe VCA protocols with minimal side effects. Our specific aims are: (1) Establishing the efficacy of a low-dose IL-2 protocol at enabling minimization of immunosuppression to sirolimus monotherapy in recipients of VCA. (2) Exploring correlations between cellular and molecular immunoassays performed in specimens from VCA recipients (and their donors) with clinical observations of stability and rejection. In future trials, these assays can be developed into tools that prospectively predict rejection and tolerance in VCA, and (3) Implementing next-generation methods to supplement and potentially overcome limitations of established methods such as histology and ultrasound biomicroscopy (UBM). We are enrolling 5 subjects for VCA. <3 months after VCA, once recipient and allograft are stable, we will administer an IL-2 based protocol intended to enable minimization of immunosuppression to sirolimus monotherapy. Afterwards, immunosuppression will be weaned. SUBJECT TERMS: NONE LISTED 16. SECURITY CLASSIFICATION OF:									
U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012	9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS		S(ES)	10.	SPONSOR/MONITOR'S ACRONYM(S)				
D.S. Almy Medical Research and Maderie Command Fort Detrick, Maryland 21702-5012 11. SPONSOR/MONITOR'S REPORT NUMBER(S) 12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY NOTES 14. ABSTRACT Safely minimizing the risks associated with vascularized composite allotransplantation (VCA) is crucial for functional restoration of wounded warriors. Our overarching goal is enabling functional and aesthetic restoration to patients with severe, unreconstructable vascularized composite tissue defects by safe VCA protocols with minimal side effects. Our specific aims are: (1) Establishing the efficacy of a low-dose IL-2 protocol at enabling minimization of immunosuppression to sirolimus monotherapy in recipients of VCA. (2) Exploring correlations between cellular and molecular immunoasays performed in specimens from VCA recipients (and their donors) with clinical observations of stability and rejection. In future trials, these assays can be developed into tools that prospectively predict rejection and tolerance in VCA, and (3) Implementing next-generation methods to supplement and potentially overcome limitations of established methods such as histology and ultrasound biomicroscopy (UBM). We are enrolling 5 subjects for VCA. <3 months after VCA, once recipient and allograft are stable, we will administer an IL-2 based protocol intended to enable minimization of immunosuppression to sirolimus monotherapy. Afterwards, immunosuppression will be weaned. SUBJECT TERMS: NONE LISTED 17. LIMITATION OF ABSTRACT Unclassified 18. NUMBER 19a. NAME OF RESPONSIBLE PERSON USAMENIC a. REPORT b. ABSTRACT c. THIS PAGE Unclassi	LLS Army Medical Desserve and Material Command								
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY NOTES 14. ABSTRACT Safely minimizing the risks associated with vascularized composite allotransplantation (VCA) is crucial for functional restoration to patients with severe, unreconstructable vascularized composite tissue defects by safe VCA protocols with minimal side effects. Our specific aims are: (1) Establishing the efficacy of a low-dose LL-2 protocol at enabling minimization of immunosuppression to sirolimus monotherapy in recipients of VCA. (2) Exploring correlations between cellular and molecular immunoasays performed in specimens from VCA recipients (and their donors) with clinical observations of stability and rejection. In future trials, these assays can be developed into tools that prospectively predict rejection and tolerance in VCA, and (3) Implementing next-generation methods to supplement and potentially overcome limitations of established methods such as histology and ultrasound biomicroscopy (UBM). We are enrolling 5 subjects for VCA. <3 months after VCA, once recipient and allograft are stable, we will administer an IL-2 based protocol intended to enable minimization of immunosuppression to sirolimus monotherapy. Afterwards, immunosuppression will be weaned. SUBJECT TERMS: NONE LISTED	C.S. Anny Medical Research and			11					
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY NOTES 14. ABSTRACT Safely minimizing the risks associated with vascularized composite allotransplantation (VCA) is crucial for functional restoration of wounded warriors. Our overarching goal is enabling functional and aesthetic restoration to patients with severe, unreconstructable vascularized composite tissue defects by safe VCA protocols with minimal side effects. Our specific aims are: (1) Establishing the efficacy of a low-dose IL-2 protocol at enabling minimization of immunosuppression to sirolimus monotherapy in recipients of VCA. (2) Exploring correlations between cellular and molecular immunoassays performed in specimens from VCA recipients (and their donors) with clinical observations of stability and rejection. In future trials, these assays can be developed into tools that prospectively predict rejection and tolerance in VCA, and (3) Implementing next-generation methods to supplement and potentially overcome limitations of established methods such as histology and ultrasound biomicroscopy (UBM). We are enrolling 5 subjects for VCA. <3 months after VCA, once recipient and allograft are stable, we will administer an IL-2 based protocol intended to enable minimization of immunosuppression to sirolimus monotherapy. Afterwards, immunosuppression will be weaned. SUBJECT TERMS: NONE LISTED	For Detrick, Maryland 21702-501	2			NIMBED(S)				
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY NOTES 14. ABSTRACT Safely minimizing the risks associated with vascularized composite allotransplantation (VCA) is crucial for functional restoration of wounded warriors. Our overarching goal is enabling functional and aesthetic restoration to patients with severe, unreconstructable vascularized composite tissue defects by safe VCA protocols with minimal side effects. Our specific aims are: (1) Establishing the efficacy of a low-dose IL-2 protocol at enabling minimization of immunosuppression to sirolimus monotherapy in recipients of VCA. (2) Exploring correlations between cellular and molecular immunoasays performed in specimens from VCA recipients (and their donors) with clinical observations of stability and rejection. In future trials, these assays can be developed into tools that prospectively predict rejection and tolerance in VCA, and (3) Implementing next-generation methods to supplement and potentially overcome limitations of established methods such as histology and ultrasound biomicroscopy (UBM). We are enrolling 5 subjects for VCA. <3 months after VCA, once recipient and allograft are stable, we will administer an IL-2 based protocol intended to enable minimization of immunosuppression to sirolimus monotherapy. Afterwards, immunosuppression will be weaned. SUBJECT TERMS: NONE LISTED 16. SECURITY CLASSIFICATION OF: 17. LIMITATION Unclassified 18. NUMBER OF PAGES 6 19a. NAME OF RESPONSIBLE PERSON USAMRMC a. REPORT b. ABSTRACT c. THIS PAGE Unclassified 18. NUMBER Or PAGES 19b. TELEPHONE NUMBER (include area code)					NUMBER(S)				
Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY NOTES 14. ABSTRACT Safely minimizing the risks associated with vascularized composite allotransplantation (VCA) is crucial for functional restoration to patients with severe, unreconstructable vascularized composite tissue defects by safe VCA protocols with minimal side effects. Our specific aims are: (1) Establishing the efficacy of a low-dose IL-2 protocol at enabling minimization of immunosuppression to sirolimus monotherapy in recipients of VCA. (2) Exploring correlations between cellular and molecular immunoassays performed in specimens from VCA recipients (and their donors) with clinical observations of stability and rejection. In future trials, these assays can be developed into tools that prospectively predict rejection and tolerance in VCA, and (3) Implementing next-generation methods to supplement and potentially overcome limitations of established methods such as histology and ultrasound biomicroscopy (UBM). We are enrolling 5 subjects for VCA. <3 months after VCA, once recipient and allograft are stable, we will administer an IL-2 based protocol intended to enable minimization of immunosuppression to sirolimus monotherapy. Afterwards, immunosuppression will be weaned.	12. DISTRIBUTION / AVAILABILITY STA	TEMENT							
13. SUPPLEMENTARY NOTES 14. ABSTRACT Safely minimizing the risks associated with vascularized composite allotransplantation (VCA) is crucial for functional restoration of wounded warriors. Our overarching goal is enabling functional and aesthetic restoration to patients with severe, unreconstructable vascularized composite tissue defects by safe VCA protocols with minimal side effects. Our specific aims are: (1) Establishing the efficacy of a low-dose IL-2 protocol at enabling minimization of immunosuppression to sirolimus monotherapy in recipients of VCA. (2) Exploring correlations between cellular and molecular immunoassays performed in specimens from VCA recipients (and their donors) with clinical observations of stability and rejection. In future trials, these assays can be developed into tools that prospectively predict rejection and tolerance in VCA, and (3) Implementing next-generation methods to supplement and potentially overcome limitations of established methods such as histology and ultrasound biomicroscopy (UBM). We are enrolling 5 subjects for VCA. <3 months after VCA, once recipient and allograft are stable, we will administer an IL-2 based protocol intended to enable minimization of immunosuppression to sirolimus monotherapy. Afterwards, immunosuppression will be weaned. SUBJECT TERMS: NONE LISTED 17. LIMITATION OF ABSTRACT Unclassified 19a. NAME OF RESPONSIBLE PERSON USAMRMC 6 19a. NAME OF RESPONSIBLE PERSON USAMRMC 19b. TELEPHONE NUMBER (include area code)	Approved for Public Release; Dist	ribution Unlimited							
14. ABSTRACTSafely minimizing the risks associated with vascularized composite allotransplantation (VCA)is crucial for functional restoration of wounded warriors. Our overarching goal is enablingfunctional and aesthetic restoration to patients with severe, unreconstructable vascularizedcomposite tissue defects by safe VCA protocols with minimal side effects. Our specific aimsare: (1) Establishing the efficacy of a low-dose IL-2 protocol at enabling minimization ofimmunosuppression to sirolimus monotherapy in recipients of VCA. (2) Exploring correlationsbetween cellular and molecular immunoassays performed in specimens from VCA recipients (andtheir donors) with clinical observations of stability and rejection. In future trials, theseassays can be developed into tools that prospectively predict rejection and tolerance in VCA,and (3) Implementing next-generation methods to supplement and potentially overcomelimitations of established methods such as histology and ultrasound biomicroscopy (UBM).We are enrolling 5 subjects for VCA. <3 months after VCA, once recipient and allograft are	13. SUPPLEMENTARY NOTES								
16. SECURITY CLASSIFICATION OF: 17. LIMITATION OF ABSTRACT 18. NUMBER OF PAGES 19a. NAME OF RESPONSIBLE PERSON USAMRMC a. REPORT b. ABSTRACT c. THIS PAGE Unclassified 6 19b. TELEPHONE NUMBER (include area code) Unclassified Unclassified Unclassified 10 10	14. ABSTRACT Safely minimizing the risks associated with vascularized composite allotransplantation (VCA) is crucial for functional restoration of wounded warriors. Our overarching goal is enabling functional and aesthetic restoration to patients with severe, unreconstructable vascularized composite tissue defects by safe VCA protocols with minimal side effects. Our specific aims are: (1) Establishing the efficacy of a low-dose IL-2 protocol at enabling minimization of immunosuppression to sirolimus monotherapy in recipients of VCA. (2) Exploring correlations between cellular and molecular immunoassays performed in specimens from VCA recipients (and their donors) with clinical observations of stability and rejection. In future trials, these assays can be developed into tools that prospectively predict rejection and tolerance in VCA, and (3) Implementing next-generation methods to supplement and potentially overcome limitations of established methods such as histology and ultrasound biomicroscopy (UBM). We are enrolling 5 subjects for VCA. <3 months after VCA, once recipient and allograft are stable, we will administer an IL-2 based protocol intended to enable minimization of immunosuppression to sirolimus monotherapy. Afterwards, immunosuppression will be weaned. SUBJECT TERMS: NONE LISTED								
of ABSTRACT OF ABSTRACT OF PAGES USAMRMC a. REPORT b. ABSTRACT c. THIS PAGE 6 19b. TELEPHONE NUMBER (include area code) Unclassified Unclassified Unclassified Inclassified Inclassified	16. SECURITY CLASSIFICATION OF		17. LIMITATION	18. NUMBER	19a. NAME OF RESPONSIBLE PERSON				
a. REPORT b. ABSTRACT c. THIS PAGE 6 19b. TELEPHONE NUMBER (include area code) Unclassified Unclassified Unclassified 6			OF ABSTRACT	OF PAGES	USAMRMC				
Unclassified Unclassified Unclassified	a. REPORT b. ABSTRACT	c. THIS PAGE	Unclassified	6	19b. TELEPHONE NUMBER (include area code)				
	Unclassified Unclassified	I Unclassified							

Standard Form 298 (Rev. 8-98) Prescribed by ANSI Std. Z39.18

Contents

1.	Introduction	4
2.	Key Words:	5
3.	Accomplishments	5
4.	Impact	5
5.	Changes/Problems	6
6.	Products	6
7.	Publications, Abstracts and Presentations	6
8.	Inventions, Patents and Licenses	6
9.	Reportable Outcomes	6
10.	Other Achievements	6
11.	Participant and other collaborating organizations	7
12.	Special Reporting Requirements	7
13.	Appendices	7

1. Introduction

Many individuals lose parts of their faces, their limbs or their abdomen in traumatic incidents such as active combat, burns, gunshot wounds, violent attacks, and motor vehicle accidents, amongst others. People with these types of traumatic injuries have decreased quality of life, and are often disabled. Although they may receive the best of the available conventional reconstruction therapies, they continue to suffer from chronic pain, psychological distress, social isolation, and limitations in their ability to perform daily activities such as bathing, dressing, ambulating, and eating without substantial help. "Vascularized composite allotransplantation", or "VCA" for short, is a new promising therapy for these types of patients. Face transplants, hand transplants and abdominal wall transplants are examples of types of VCA.

The most significant disadvantage of VCA is that patients who receive this therapy must take immunosuppressive drugs for the rest of their lives in order to prevent their bodies from rejecting the transplant. Immunosuppressive drugs pose significant health risks. As VCA is not a life-saving therapy, the risks of immunosuppressive drugs are given much more consideration than in the case of, for example, a heart transplant. Therefore, many people who would benefit from VCA end up not receiving the therapy due to concerns about immunosuppression. We have developed a novel, safe treatment that may enable patients who receive VCA to drastically reduce or even completely eliminate immunosuppressive drugs in the months after transplantation. The objective of this study is to test this novel treatment in 5 patients who will receive VCA. At least 3 months after their VCA operations, our patients will receive our novel treatment which is based on low doses of "interleukin-2" or "IL-2" for short, over a period of 3-4 months. After receiving IL-2 treatment, we will try to minimize or possibly stop immunosuppressive drugs in our patients. If, however, we see signs of rejection, we give standard immune suppression back, which stops rejection successfully in the vast majority of VCA patients. We will follow the progress of our patients for 24 months thereafter. Using state of the art molecular, cellular and imaging technologies, we monitor the subjects' immune status to identify patients who can safely minimize immune suppression and those who are likely to suffer rejection.

VCA will give many patients the opportunity to improve their quality of life and regain social participation and independence. Our study is carefully designed to thoroughly inform the patients about risks and benefits of participation, to minimize the incidence of complications, and if it is not possible to avoid them, have a safe treatment plan.

2. Key Words:

Vascularized composite allotransplantation, immune modulation, immune tolerance, IL-2

3. Accomplishments.

In April 2018, we we have performed a face transplant on the first patient and started the IL-2 protocol in October 2018. The patient is currently stable on IL-2 for almost a year and did not have any acute rejections nor side-effects of the immunosuppression. He receives IL-2 injections every third day and his tacrolimus levels are maintained at 6-8 ng/ml. Prednisone and mycophenolate were successfully weaned. We are continuing the IL-2 protocol in this patient given the positive preliminary results.

In July 2019, we have performed a face transplant on the second patient after being almost 1.5 years on waitlist. The surgery was successful and we expect to start IL-2 protocol in this patient in 3-4 months if no complications occur.

In the meantime, we have:

- Reported to the FDA and maintained IND approval for use of IL-2 in this patient population
- Discussed methods to recruit additional candidates

In addition, we have kept up with our monthly teleconference calls with the sponsor, as well as maintained up to date reporting requirements.

4. Impact

Active combat is inflicting multiple devastating injuries to unprotected body areas such as the face and limbs with alarming incidence, and resulting in limb amputation, facial disfigurement, and loss of abdominal wall. Conventional reconstructive surgery is limited in its ability to restore form and function after these injuries. Disability with associated long-term medical care and disability benefit costs is common. Considering the high incidence and devastating consequences of these complex injuries to American Service members, there is a clear need to improve their treatment outcomes. Vascularized composite allotransplants provide a mean to functionally and cosmetically restore these tissues; however, at the cost of lifelong immunosuppression. If successful, these studies will facilitate induction of immunologic tolerance to the transplanted tissues thus improving the rate of return to duty, deployment and function of American service members and veterans recovering from combat-related limb loss, with associated improvements in quality of life, mental health, social participation and the American economy.

5. Changes/Problems

One of the most significant roadblocks in this project has been the slower subject recruitment than anticipated. This was due to low volume of referrals, and no military referrals. We are doing everything we can to get more patient candidate referrals. Three transplant candidates that contacted our center were not found eligible for transplant past year. Due to the slow recruitment rate we have processed a no-cost extension to extend for an additional year and this was approved in August 2018. We have advertised our study in Plastic Surgery News periodical, and will explore longer duration, as well as other professional magazines. We also reached out to our colleagues at MGH to team up in patient recruitment.

6. Products

Nothing to report at this time.

7. Publications, Abstracts and Presentations

Part of the data from the first patient will be presented at Military Health System Research Symposium (MSHRS) Conference 2019, Kissimmee, Florida, Aug 19-22.

8. Inventions, Patents and Licenses

Nothing to report at this time.

9. Reportable Outcomes

Nothing to report at this time.

10. Other Achievements

Nothing to report at this time.

11. Participant and other collaborating organizations

Our collaboration with the Massachusetts Institute of Technology remain in place and active; we have obtained ceded review from their institutional IRB so that their contribution to our studies remains under oversight by the Partners Human Research Committee. Due to the passing of our collaborator at Beth Israel Deaconess Medical Center this past year that collaboration has been terminated and the responsibilities of the BIDMC have been transferred back to Dr. Riella at BWH.

12. Special Reporting Requirements

None.

13. Appendices

None.

Novel strategies to improve immunomodulation and non-invasive clinical monitoring in VCA

W81XWH-15-2-0031 MR140159

PI: Bohdan Pomahac

Org: Brigham and Women's Hospital

Award Amount: \$2,487,729

Study/Product Aim(s)

• SA1. To develop a safe and feasible regimen for minimization of immune suppression in recipients of VCA through daily subcutaneous low-dose rIL-2.

• SA 2. To explore correlations between cellular and molecular immune markers in VCA and clinical observations of immune stability and rejection.

• SA3. To develop non-invasive technologies to monitor for VCA rejection, such as next-generation MR methods.

Approach

Exploratory, open-label, prospective safety and feasibility clinical trial that will enroll 5 candidates for VCA.
Five subjects will be recruited and enrolled for VCA.
Following VCA, they will receive an IL-2 drug protocol.
Specimens and imaging data from these VCA recipients will be used towards SA2 and SA3.

Timeline and Cost

Activities CY	15	16	17	18
Task 1. DOD and IRB approval				
Task 2. Enrollment of 5 subjects				
Task 3. VCA surgeries				
Task 4. Administration of IL-2 protocol				
Estimated Budget (\$K)	\$273,737	\$597,244	\$597,244	\$323,507

Updated: August 2019

Figure 1. Post-operative frontal view of three full-facial recipients at BWH, 17 months (left), 18 months (center) and 12 months (right) after the operation.

IRB and HRPO approval obtained.

Goals/Milestones

CY17 Goal – IRB/HRPO approval

- ☑ Both IRB and HRPO approved
- CY17 Goal Enrollment of 5 subjects
- ☑ Informed consent 2/5 subjects
- ☑ Screening 2/5 subjects
- CY18 Goal VCA surgeries
- \Box 5 subjects 2/5 surgeries
- CY18 Goal Administration of IL-2
- □ In 5 subjects 1/5 Subjects

Comments/Challenges/Issues/Concerns

• Timelines have changed with respect to the original proposal because of delays in obtaining IRB/HRPO approval as well as slow subject recruitment.

Budget Expenditure to Date

Projected Expenditure: \$2,487,729 Actual Expenditure: \$1,806,328

